Single Cell Proteomics | Each Cell Makes a Difference

Powerful Biology
Accelerating the
Future of Medicine

The future of advanced medicines relies upon deeper access to in vivo biology to create durable, curative impacts on disease. Our systems, which drive convergence of dynamic proteomics and single cell biology for the first time, are creating this deeper connection to accelerate curative medicines.

Request a Quote

Introducing IsoSpark

Introducing the IsoSpark

A personalized functional
proteomics system for any lab.

Learn More

Bridging the Gap to Accelerate Medicine

Isoplexis captures proteomics reflecting in vivo biology with walk-away automation to cut therapeutic development timelines and add efficacy

Proteins Reflecting & Predicting
in vivo Biology

High MultiPlex from Single Cells & Bulk Captures Complexity

Time Saved with
Analytics Automation

Single-Cell Functional Proteomics Hub

Accelerate your therapeutics and biomarkers
with an all-in-one integrated system

Learn More

Our Solutions

The Products Driving Our Superpowered Biology

Better Biomarkers,
Accelerated Development

Functional Immune
Landscaping

Accelerate the ability to clarify lead candidate choice and durable biomarkers using the proteomic secretome from each single cell to accelerate path to the clinic and higher efficacy with targeted immune therapies.

Accelerated Discovery
and Targeting

Intracellular Signaling
Omics

Identify adaptive phosphoproteomic signaling networks from rare subsets of single tumor and other cell types, leveraging single cell proteomics to treat the entire set of signaling pathways concurrently, and eliminate resistance and metastases.

Icon-Square-High-plex-Automated-Immunoassays-Transparent-BG-white@2x

Sample to Insights,
for Any Lab

High-plex Walk-Away
Immunoassays

For the first time, unleash walk-away multiplexed proteomics in very low sample volumes, with an analytics suite that saves resources and time while delivering key omic insights.

Technology

Superpowered Biology Built on a Strong Foundation

Our Unique Biology

Immune
Cells

Tumor

Proteomics, Reimagined to uniquely detect our most powerful cells.

Explore Our Biology

Instrument Virtual Demo

The entire ELISA proteomics workflow, sample to answer.

Take the Virtual Tour

Data Visualization Tour

IsoSpeak Software: Same day visualizations and insights.

Tour the Visualizations

Publications

See how top researchers are using our technology to predict durable responses and unlock pre-clinical meaning.

View All Publications

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel et al., Nature Medicine. 2021.

View Publication

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Adi Diab et al., Journal of Clinical Oncology. 2021.

View Publication

Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19

Yapeng Su et al., Cell . 2020.

View Publication

Areas of Interest

See how we can shift the paradigms in your programs

Cancer
Immunology

IsoPlexis’ Functional Immune landscaping for liquid T cell biopsies is showing which therapies work with which patients with unique insights.

Cell
Therapy

Quality Analytics with IsoPlexis’ functional immune landscaping are shaping the future of cell therapy and enabling more efficient manufacturing, higher quality cell therapies, and improved patient outcomes.

Infectious
Disease

COVID-19 and other complex diseases are being advanced with IsoPlexis’ functional immune-landscaping and high-plex automated immunoassays to speed insights.

Inflammation

IsoPlexis’ high-plex automated immunoassays and functional immune landscaping are providing immediate insights into the drivers of immune inflammation.

Targeted
Therapies

IsoPlexis’ intracellular signaling omics are revealing mechanisms of the functional cellular adaptations leading to resistance and providing insights for the development of better targeted therapies.

Updates

Enabling a New Era of Precision Medicine

Latest Customer Stories View Blog

Sep 09

Single-Cell Functional Proteomics Discovers a Potential Target for Enhancing NK Cell-Based Cancer Immunotherapy

Cell Therapy

Aug 30

Published in Nature Medicine: Utilizing IsoPlexis’ Single-Cell Proteomics and Product Quality Metrics in a Phase I Trial of TIL treatment for Metastatic Lung Cancer

Cancer Immunology

Aug 13

Single-Cell Functional Biomarkers for Each Stage of the Cell Therapy Development Pipeline

CAR T Therapy | Cell Therapy | Cellular and Regenerative Medicine

Featured Events All Events

AGBT Precision Health

Conference

Sep 9-11 | VIRTUAL & SAN DIEGO, CA

View Event

Festival of Biologics – EU

Conference

Nov 9 - 11 | Congress Centre Basel

View Event

SITC

Conference

Nov 10 - 14 | VIRTUAL

View Event

Featured Content

The IsoSpark Brochure

Accelerate immune medicine across research areas & high-impact applications. All in one, beautifully designed and intuitive system that fits on any lab bench. Across all applications, discover immune profiling insights unattainable with any other system.

Download Now

quote-isospark-solid-gradient-smooth-green@2x

Trusted Worldwide

We innovated the only way to measure the true function of each cell and identify the rare subsets of superpowered cells driving response.

As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.

Christine Brown

City of Hope

The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood.

Petter Brodin, MD PHD

Associate Professor of Immunology at Karolinska Institute

Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.

Marco L Davila

Moffitt Cancer Center

We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.

Jon Zalevsky

Chief Scientific Officer, Nektar Therapeutics

Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.

Adrian Bot, MD

Vice President, Translation Sciences, Kite

Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.

John Rossi

Director of Translational Sciences at Kite

“The best way to predict the future is to invent it.”

— Alan Kay

Spark the Next Breakthrough

Speak to an Expert